Update on cancer control in women

International Journal of Gynecology and Obstetrics

Volumn 70, Issue 2, 2000, Pages 263-303

  Boyle, P ^a   Maisonneuve, P ^a   Autier, P ^a  

^a EUROPEAN INSTITUTE OF ONCOLOGY   (Italy)

Author keywords

Cancer; Cigarette smoking; Hormone replacement therapy; Oral contraceptives; Screening

Indexed keywords

ORAL CONTRACEPTIVE AGENT;

BREAST CANCER; CANCER CONTROL; CANCER INCIDENCE; CANCER MORTALITY; CANCER RISK; CANCER SCREENING; CIGARETTE SMOKING; ENDOMETRIUM CANCER; FEMALE; GYNECOLOGIC CANCER; HORMONE SUBSTITUTION; HUMAN; MORTALITY; OVARY CANCER; PRIORITY JOURNAL; REVIEW; UTERINE CERVIX CANCER; VAGINA CANCER; WART VIRUS;

EID: 0034253767     PISSN: 00207292     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0020-7292(00)00298-8     Document Type: Review

References (178)

1. 23rd FIGO Annual Report on the Results of Treatment in Gynecological cancer. J Epidemiol Biostatics 1998;3(1).
2. National Cancer Institute of Canada. Canadian Cancer Statistics 1997. Canadian Cancer Society. Toronto, Canada, 1997.
3. Doll R., Peto R. The causes of cancer: quantitative estimates of avoidable risks of cancer in the United States today. J Natl Cancer Inst. 66:1981;1191-1308.
4. International Agency for Research on Cancer. Monographs on the evaluation of carcinogenic risk to humans. Volume 38. Tobacco smoking. 1986;IARC, Lyon.
5. Boyle P. Cancer, cigarette smoking and premature death in Europe. A review including the Recommendations of European Cancer Experts Consensus Meeting, Helsinki, October 1996. Lung Cancer. 17:1997;1-60.
6. International Agency for Research on Cancer. Monographs on the evaluation of carcinogenic risk to humans Volume 44. Alcohol drinking. 1988;IARC, Lyon.
7. Boyle P., La Vecchia C., Maisonneuve P., Zheng T., Macfarlane G.J. Cancer epidemiology and prevention. Peckam M.J., Pinedo H., Veronesi U. Oxford textbook of oncology. 1995;199-273 Oxford Medical Publications, Oxford.
8. Boyle P. Epidemiology of breast cancer. Bailliere's Clin Oncol. 2:1988;1-59.
9. Peto R., Lopez A.D., Boreham J., Thun M., Heath C. Mortality from tobacco in developed countries: indirect estimation from national vital statistics. Lancet. 39:1992;1268-1278.
10. Boyle P., Maisonneuve P. Lung cancer and tobacco smoking. Lung Cancer. 12:1995;167-181.
11. Chollat-Traquet C. Women and tobacco. World Health Organisation. Geneva, 1992.
12. Boyle P, Maisonneuve P, Gray N. Lung cancer and breast cancer mortality in women in international populations. The Lancet, for submission.
13. Peto R. The preventability of cancer. Vessey M.P., Gray M. Cancer risks and prevention. 1985;1-15 Oxford University Press, Oxford.
14. Boyle P. Progress in preventing death from colorectal cancer. Br J Cancer. 72:1995;528-530.
15. Steinmetz K.A., Potter J.D. Vegetable, fruit, and cancer I. Epidemiology. Cancer Causes Control. 2:1991;325-358.
16. Hunter D.J., Manson J., Colditz G.A., Stampfer M.J., Rosner B., Hennekens C.H. et al. A prospective study of the intake of vitamins C, E, and A and the risk of breast cancer. New Engl J Med. 329:1993;234-240.
17. Gandini S., Merzenich H., Robertson C., Boyle P. Review on diet and breast cancer risk: the role of vegetables and fruits consumption and related vitamins. Eur J Cancer. 36(5):2000;636-646.
18. Gutensohn N., Cole P. Epidemiology of Hodgkin's disease. Seminars Oncology. 7:1980;92-102.
19. Mueller N., Evans A., Harris N.L., Comstock G.W., Jellum P.H.E., Magnus K. et al. Hodgkin's disease and Epstein-Barr virus. Altered anti-body pattern before diagnosis. New Engl J Med. 320:1989;689-695.
20. Paffenbarger RS, Wing AL, Hyde RT. Characteristics in youth indicative of adult-onset Hodgkin's disease. J Natl Cancer Inst, 1077;58:1489-1491.
21. Boiocchi M., Carbone A., DeRe V., Dolcetti R. Is the Epstein-Barr virus involved in Hodgkin's disease? Tumori. 75:1989;345-350.
22. Alexander F.E., Williams J., McKinney P.A., Ricketts T.J., Cartwright R.A. A specialist leukemia/lymphoma registry in the UK. Part 2. Clustering of Hodgkin's disease. Br J Cancer. 60:1989;948-952.
23. Boyle P, Walker AM, Alexander FE. Historical aspects of investigation of disease clusters. In: Alexander and Boyle P, editors. Statistical investigation of disease clustering. Lyon:IARC Scientific Publications, 1996.
24. Beasley R.P., Lin C., Hwang L.Y., Chien C.S. Hepatocellular carcinoma and hepatitis B virus. A prospective study of 22 707 men in Taiwan. Lancet. ii:1981;1129-1133.
25. Beasley R.P. Hepatitis B virus. The major etiology of hepatocellular carcinoma. Cancer. 61:1988;1942-1956.
26. Munoz N., Bosch F.X. HPV and cervical neoplasia: review of case-control and cohort studies. IARC Sci Publ. 119:1992;251-261.
27. Franco E., Monsonego J. New developments in cervical cancer screening and prevention. 1997;Blackwell Science, Oxford.
28. Boyle P., Maisonneuve P., Hsieh C.C. Epidemiology of breast cancer. Zatonski W., Boyle P., Tcyznski J. Cancer epidemiology: vital statistics through prevention. 1990;128-135 Interpresse, Warsaw.
29. Lee HP, Day NE, Shanmugaratnam K, editors. Trends in cancer incidence in Singapore 1968-1982. IARC Scientific Publications no. 91. Lyon, IARC, 1988.
30. Devesa S.S., Silverman D.T., Young J.L. Cancer incidence and mortality among whites in the United States, 1974-1984. J Natl Cancer Inst. 79:1987;701-702.
31. La Vecchia C., Lucchini F., Negri E., Boyle P., Maisonneuve P., Levi F. Trends of cancer mortality in Europe, 1955-89. III Breast and genital sites. Eur J Cancer. 28:1955;927-998.
32. Boyle P., La Vecchia C., Negri E., Lucchini F., Levi F. Trends in diet-related cancers in Japan: a conundrum? Letter. Lancet. 342:1993;752.
33. Peto R., Boreham J., Clarke M., Davies C., Beral V. UK and USA breast cancer deaths down 25% in year at ages 20-69 years. Lancet. 355((9217)):2000;18-22.
34. Haenszel W., Kurihara M. Studies of Japanese migrants I. Mortality from cancer and other diseases among Japanese in the United States. J Natl Cancer Inst. 40:1968;43-68.
35. Armstrong BK, Woodings TL, Stenhouse NS. Mortality from cancer in migrants to Australia 1962-1971. NH & MRSC Research Unit in Epidemiology and Preventive Medicine. University of Western Australia, 1983.
36. McCredie M., Coates M. Cancer incidence in migrants to New South Wales. Int J Cancer. 46:1990;228-232.
37. MacMahon B., Cole P., Lin T.M., Lowe C.R., Mirra A.P., Ravnihar B. et al. Age at first birth and cancer of the breast. A summary of an international study. Bull World Health Organization. 43:1970;209-221.
38. Ewertz M., Duffy S.W., Adami H.O., Kvale G., Lund E., Meirik O. et al. Age at first birth, parity and risk of breast cancer: a meta-analysis of 8 studies from the Nordic countries. Int J Cancer. 46:1990;597-603.
39. Trichopoulos D., Hsieh C.C., MacMahon B., Lin T., Lowe C.R., Mirra A.P. et al. Age at any birth and breast cancer risk. Int J Cancer. 31:1983;701-709.
40. Kvale G., Heuch I., Eide G.E. A prospective study of reproductive factors and breast cancer. I: Parity. Am J Epidemiol. 126:1987;831-841.
41. Thompson W.D., Janerich D.T. Maternal age at birth and risk of breast cancer in daughters. Epidemiology. 1:1990;101-106.
42. Colditz G.A., Willett W.C., Stampfer M.J., Hennekens C.H., Rosner B., Speizer F.E. Parental age at birth and risk of breast cancer in daughters: a prospective study among US women. Cancer Causes Control. 1:1990;31-36.
43. Trichopoulos D. Is breast cancer initiated in utero? Epidemiology. 1:1990;95-96.
44. Panagiotopolou K., Katsouyani K., Petridou E., Garas Y., Tzonou A., Trichopoulos D. Maternal age, parity and pregnancy estrogens. Cancer Causes Control. 1:1990;119-124.
45. Bucallosi P., Veronesi U. Researches on the etiological factors in human breast cancer. Acta Union Int Contre Cancer. 15:1959;1056-1060.
46. Ewertz M., Duffy S.W. Risk of breast cancer in relation to reproductive factors in Denmark. Br J Cancer. 58:1988;99-104.
47. Herity B.A., O'Halloran M.J., Bourke G.J., Wilson-Davies K. A study of breast cancer in Irish women. Br J Prev Soc Med. 29:1975;178-181.
48. Trichopoulos D., MacMahon B., Cole P. Menopause and breast cancer risk. J Natl Cancer Inst. 48:1972;605-613.
49. Skegg D.C.G. Alcohol, coffee, fat and breast cancer editorial. Br Med J. 295:1987;1011-1012.
50. London S.J., Colditz G.A., Stampfer M.J., Willett W.C., Rosner B.A., Corsano K. et al. Lactation and risk of breast cancer in a cohort of US women. Am J Epid. 132:1990;17-26.
51. Pike MC, Henderson BE, Casagrande JT, Rosario I, Gray GE. Oral contraceptive use and early abortion as risk factors for breast cancer in young women. Br J Cancer 43:72-79.
52. Howe H.L., Senie R.T., Bzduch H., Herzfeld P. Early abortion and breast cancer risk among women under age 40. Int J Epidemiol. 18:1989;300-304.
53. Lipworth L., Katsouyanni K., Ekbom A., Michels K.B., Trichopoulos D. Abortion and the risk of breast cancer: a case-control study in Greece. Int J Cancer. 61(2):1995;181-184.
54. Daling J.R., Brinton L.A., Voigt L.F., Weiss N.S., Coates R.J., Malone K.E. et al. Risk of breast cancer among white women following induced abortion. Am J Epidemiol. 144(4):1996;373-380.
55. McGregor D.H., Land C.E., Choi K., Tokuoka S., Liu P.I., Wagabayashi T. et al. Breast cancer incidence among atomic bomb survivors, Hiroshima and Nagasaki, 1950-1969. J Natl Cancer Inst. 59:1977;799-811.
56. Shore R.E., Hempelmann L.H., Kowaluk E., Mansur P.S., Pasternack B.S., Albert R.E. et al. Breast neoplasms in women treated with X-rays for acute postpartum mastitis. J Natl Cancer Inst. 59:1977;813-822.
57. Boice J.D., Monson R.R. Breast cancer in women after repeated fluoroscopic examinations of the chest. J Natl Cancer Inst. 59:1977;823-832.
58. Boice J.D., Stone B.J. Interaction between radiation and other breast cancer risk factors. Late biological effects of ionising radiation, vol 1. 1978;231-249 IAEA, Vienna.
59. Modan B., Chetrit A., Alfandary E., Katz L. Increased risk of breast cancer after low-dose irradiation. Lancet. i:1989;629-631.
60. de Waard F., Baanders-van Halewijn E.A., Huizinga J. The bimodal age distribution of patients with mammary carcinoma. Cancer. 17:1964;141-151.
61. Swanson C.A., Jones D.Y., Schatzkin A., Brinton L.A., Ziegler R.G. Breast cancer risk assessed by anthropometry in NHANES 1 epidemiological follow-up study. Cancer Res. 48:1988;5363-5367.
62. Frisch R.E., Wyshak G., Albright N.L., Albright T.E., Schiff I., Jones K.P. et al. Lower prevalence of breast cancer and cancers of the reproductive system among former college athletes compared to non-athletes. Br J Cancer. 52:1985;885-891.
63. Warren M.P. The effects of exercise on pubertal progression and reproduction function in girls. J Clin Endocrinol Metabol. 51:1980;1150-1157.
64. Willett W.C. The search for the causes of breast and colon cancer. Nature. 338:1989;389-394.
65. Boyle P., Leake R.E. Progress in understanding breast cancer: epidemiologic and biologic interactions. Breast Cancer Res Treatment. 11:1986;91-112.
66. Boyd N.F., Martin L.J., Noffel M., Lockwood G.A., Tritchler D.L. A meta-analysis of studies of dietary fat and breast cancer risk. Br J Cancer. 68:1993;627-636.
67. Spitzer W.O. Meta-analysis: unanswered questions about aggregating data. J Clin Epid. 44:1991;103-107.
68. Hunter D.J., Spiegelman D., Adami H.O., Beeson L., van der Brandt P.A., Folsom A.R. et al. Cohort studies of fat intake and the risk of breast cancer - a pooled analysis. N Engl J Med. 334:1996;356-361.
69. Martin-Moreno J.M., Boyle P., Gorgojo L., Maisonneuve P., Fernandez-Rodriguez J.C., Willett W.C. et al. Dietary fat, olive oil intake and breast cancer risk. Int J Cancer. 58:1994;774-780.
70. Trichopolou A., Katsouyanni K., Stuver S., Tzala L., Gnardella C., Rimm E. et al. Consumption of olive oil and specific food groups in relation to breast cancer risk in Greece. J Natl Cancer Inst. 87:1995;110-116.
71. La Vecchia C., Negri E., Franceschi S., Decarli A., Giacosa A., Lipworth L. Olive oil, other dietary fats and the risk of breast cancer Italy. Cancer Causes Control. 6:1995;545-550.
72. Minchovicz J.J., Bradlow H.L. Induction of estradiol metabolism by dietary indole-3-carbinol in humans. J Natl Cancer Inst. 82:1990;947-949.
73. Griffiths K, Aldercrevtz H, Boyle P, Denis L, Marton M. Nutrition and Cancer, ISIS Medical Communications. Oxford, 1996.
74. Willett W.C., Stampfer M.J., Colditz G.A., Rosner B.A., Hennekens C.H., Speizer F.E. Moderate alcohol consumption and risk of breast cancer. New Engl J Med. 316:1987;1174-1180.
75. Longnecker M.P. Alcoholic beverage consumption in relation to risk of breast cancer: meta-analysis and review. Cancer Causes Control. 5:1994;73-82.
76. Prentice R.L., Thomas D.B. On the epidemiology of oral contraceptives and diseases. Adv Cancer Res. 49:1987;285-401.
77. Breast cancer and hormonal contraceptives: collaborative reanalysis of individual data on 53 297 women with breast cancer and 100 239 women without breast cancer from 54 epidemiological studies. Lancet. 347:1966;1713-1727.
78. Colditz G.A., Hankinson S.E., Hunter D.J., Willet W.C., Manson J.E., Stampfer M.J. et al. The use of oestrogens and progestins and the risk of breast cancer in post-menopausal women. N Engl J Med. 332:1995;1589-1593.
79. Breast cancer and hormone replacement therapy. Lancet. 350:1997;1047-1059.
80. Hulka B.S., Liu E.T., Lininger R.A. Steroid hormones and risk of breast cancer. Cancer. 74:1994;1111-1124.
81. Breast cancer and hormone replacement therapy. Lancet. 350:1997;1047-1059.
82. Baron J.A. Smoking and oestrogen-related disease. Am J Epid. 119:1984;9-22.
83. Macklin M.T. Comparison of the number of breast cancer deaths observed in the relatives of breast cancer patients, and the number expected on the basis of mortality rates. J Natl Cancer Inst. 22:1959;927-951.
84. Goudie B.M., Burt A.D., Boyle P. Breast cancer in women with primary biliary cirrhosis. Br Med J. 291:1985;1597-1598.
85. MacMahon B. A biologic framework for the risk factors for breast cancer. Adv Oncol. 10:1994;2-10.
86. Hakama M, Magnus K, Petterson F, Storm H, Tulinius H. Effect of organised screening on the risk of cervix cancer in the Nordic countries. In: Cancer screening. In: AB Miller, J Chamberlain, NE Day, M Hakama, PC Prorock, editors. International Union Against Cancer, Geneva, 1991.
87. Muñoz N, Bosch FX, Jensen OM, editors. Human papillomavirus and cervical cancer. IARC Scientific Publications no. 94. International Agency for Research on Cancer. Lyon, 1989.
88. Cuzick J., Boyle P. Trends in cervix cancer mortality. Cancer Surv. 7(3):1988;417-439.
89. Shanmugaratnam K., Muir C.S., Tow S.H. Rates per 100 000 births and incidence of chriocarcinoma and malignant mole in Singapore Chinese and Malays. Comparison with Connecticut, Norway and Sweden. Int J Cancer. 8:1971;165-175.
90. Bracken M.B., Brinton L.A., Hayashi K. Epidemiology of hydatidiform mole and choriocarcinoma. Epidemiol Rev. 6:1984;52-75.
91. Young JL, Percy CL, Asire AJ, editors. Surveillance, epidemiology and end results. Incidence and mortality data 1973-77. NCI Monograph 57. NIH Publication no. 81-2330. National Cancer Institute. Bethesda, 1981.
92. Austin D.F., Roe K.M. The decreasing incidence of endometrial cancer: public health implications. Am J Public Health. 72:1982;65-68.
93. Vonka V., Kanka J., Roth Z. Herpes simplex type 2 virus and cervical neoplasia. Adv Cancer Res. 48:1987;149-191.
94. Vonka V., Kanka J., Jelinek I., Subrt I., Suchanek A., Havrankova A. et al. Prospective study on the relationship between cervical neoplasia and herpes-simplex type-2 virus I. Epidemiological characteristics. Int J Cancer. 33:1984;49-60.
95. Brinton L.A., Fraumeni J.F. Epidemiology of uterine cervical cancer. J Chron Dis. 39:1986;1051-1065.
96. Brinton L.A., Hamman R.F., Huggins G.R. Sexual and reproductive risk factors for invasive squamous cell cervical cancer. J Natl Cancer Inst. 79:1987;23-30.
97. Brinton L.A., Reeves W.C., Brenes M.M. Parity as a risk factor for cervical cancer. Am J Epidemiol. 130:1989;486-496.
98. Invasive cervical cancer and combined oral contraceptives. Br Med J. 290:1985;961-965.
99. Brinton LA, Huggins GR, Lehmann HF. Long-term use of oral contraceptives and risk of invasive cervical cancer. Int J Cancer 1096;38:339-344.
100. La Vecchia C., Franceschi S., Decarli A. Cigarette smoking and the risk of cervical neoplasia. Am J Epidemiol. 123:1986;22-29.
101. Working group on evaluation of cervical screening programmes. Screening for squamous cervical cancer: duration of low risk after negative results of cervical cytology and its implication for screening policies. Br Med J. 293:1986;659-664.
102. Lew E.A., Garfinkel L. Variations in mortality by weight among 750 000 men and women. J Chron Dis. 32:1979;563-576.
103. Ziel H.K., Finkle W.D. Increased risk of endometrial carcinoma among users of conjugated estrogens. N Engl J Med. 293:1975;1167-1170.
104. Parazzini F., Negri E., La Vecchia C. Population attributable risk for endometrial cancer in northern Italy. Eur J Cancer Clin Oncol. 25(1):1989;451-1456.
105. Grady D., Rubin S.M., Pettiti D.B., Fox C.S., Black D., Ettinger B. et al. Hormone therapy to prevent disease and prolong life in post-menopausal women. Ann Int Med. 117:1992;1016-1037.
106. The writing committee for the PEPI trial. Effects of hormone replacement therapy on endometrial histology in postmenopasual women. J Am Med Assoc. 275:1996;370-375.
107. Persson I., Adami H.O., Berkvist L. Risk of endometrial cancer after treatment with oestrogen's alone or in conjunction with progestogens: results of a prospective study. Br Med J. 298:1989;1476-2151.
108. Persson I., Schmidt M., Adami H.O., Bergstrom R., Petterson B., Sparen P. Trends in endometrial cancer incidence and mortality in Sweden, 1960-1984. Cancer Causes Control. 1:1990;201-208.
109. Schlesselman J.J. Oral contraceptives and neoplasia of the uterine corpus. Contraception. 43:1991;557-579.
110. Wynder E.L., Escher G.C., Mantel N. An epidemiological investigation of cancer of the endometrium. Cancer. 19:1966;489-520.
111. Olaya F, Nectoux J. Le cancer en Ardèche du Nord. Incidence 1983-86. Registre des Tumeurs de l'Ardèche du Nord. Annonay, 1987.
112. Pike M.C. Age-related factors in cancers of the breast, ovary, and endometrium. J Chron Dis. 2(40):1987;595-695.
113. Rosenberg L., Shapiro S., Slone D. Epithelial ovarian cancer and combination oral contraceptives. J Am Med Assoc. 247:1982;3210-3212.
114. La Vecchia C., Franceschi S., Decarli A. Oral contraceptive use and the risk of epithelial ovarian cancer. Br J Cancer. 50:1984;31-34.
115. Study of the centers for disease control and the National Institute of Child Health and Human Development. The reduction in risk of ovarian cancer associated with oral-contraceptive use. N Engl J Med. 316:1987;650-655.
116. Epithelial ovarian cancer and combined oral contraceptives. Int J Epidemiol. 18:1989;538-545.
117. Adami H.O., Bergstrom R., Persson I., Sparen P. The incidence of ovarian cancer in Sweden, 1960-1984. Am J Epidemiol. 132:1990;446-452.
118. Ries LAG, Kosary CL, Hankey BF, Miller BA, Harras A, Edwards BK, editors. SEER Cancer Statistics Review 1973-1994. National Cancer Institute. NIH Pub. No. 97-2789. Bethesda, MD, 1997.
119. Balzi D., Carli P., Geddes M. Malignant melanoma in Europe: changes in mortality rates (1970-90) in European community countries. Cancer Causes Control. 8:1997;85-92.
120. Gilles G.G., Armstrong B.K., Burton R.C., Staples M.P., Thursfield V.J. Has mortality form melanoma stopped rising in Australia? Analysis of trends between 1931 and 1994. Br Med J. 312:1996;1121-1125.
121. Autier P., Doré J.F., Lejeune F., Koelmel K.F., Geffeler O., Hille P. et al. Recreational exposure to sunlight and lack of information as risk factors for cutaneous malignant melanoma. Results of an European Organisation for Research and Treatment of cancer EORTC case-control study in Belgium, France and Germany. Melanoma Res. 4:1994;79-85.
122. Elwood M., Jopson J. Melanoma and sun exposure: an overview of published studies. Int J Cancer. 73:1997;198-203.
123. Boldeman C., Beitner H., Jansson B., Nilsson B., Ullen H. Sunbed use in relation to phenotype, erythema, sunscreen use and skin disease: a questionnaire survey among Swedish adolescents. Br J Dermatol. 135:1996;712-716.
124. Autier P., Doré J.F., Lejeune F., Koelmel K.F., Geffeler O., Hille P. et al. Cutaneous malignant melanoma and exposure to sunlamps or sunbeds: an EORTC multicenter case-control study in Belgium, France and Germany. Int J Cancer. 58:1994;809-813.
125. George P.M., Kuskowski M., Schmidt C. Trends in photoprotection in American fashion magazines, 1983-1993. J Am Acad Dermatol. 34:1996;424-428.
126. Autier P., Doré J.F., Renard F., Luther H., Cattaruzza S.M., Gefeller O. et al. Melanoma and sunscreen use: need for studies representative of actual behaviours. Mel Res. 7(2):1997;S115-S120.
127. Autier P., Dore J.F., Shifflers E., Cesarini J.P., Bollaerts A., Koelmel K.F. et al. Melanoma and use of sunscreens: an EORTC case-control study in Germany, Belgium and France. Int J Cancer. 61:1995;749-755.
128. International Agency for Research on Cancer. Solar and ultraviolet radiation. Monographs on the evaluation of the carcinogenic risk of chemicals to humans. Vol 55. Lyon, 1992.
129. MacLennan S.C., MacLennan A.H., Ryan P. Colorectal cancer and oestrogen replacement therapy: a meta-analysis of epidemiological studies. Med J Austr. 162:1991;491-493.
130. Jacobs E.J., White E., Weiss N.S. Exogenous hormones, reproductive history and colon cancer. Cancer Causes Control. 5:1994;359-366.
131. Calle E.E., Miracle-McMahill H.L., Thun M.J., Heath C.W. Estrogen replacement therapy and risk of fatal colon cancer in a prospective cohort of postmenopausal women. J Natl Cancer Inst. 87:1995;517-523.
132. Wald N.J., Chamberlain J., Hackshaw A. et al. Report of the European Society of Mastology EUSOMA Breast Cancer Screening Evaluation Committee. The Breast. 2:1993;209-216.
133. Jick S.S., Walker A.M., Jick H. Oral contraceptives and endometrial cancer. Obstet Gynecol. 82(6):1993;931-935.
134. Hill H.A., Coates R.J., Austin H., Correa P., Robboy S.J., Chen V. et al. Racial differences in tumor grade among women with endometrial cancer. Gynecol Oncol. 56(2):1995;154-163.
135. Risch H.A., Howe G.R. Menopausal hormone usage and breast cancer in Saskatchewan: a record-linkage cohort study. Amer J Epidemiol. 139:1994;670-683.
136. Schairer C., Byrne C., Keyl P.M., Brinton L.A., Sturgeon S.R., Hoover R.N. Menopausal estrogen and estrogen-progestin replacement therapy and risk of breast cancer United States. Cancer Causes Control. 5:1994;491-500.
137. Steinberg K.K., Thacker S.B., Smith S.J., Stroup D.F., Zack M.M., Flanders W.D. et al. A meta-analysis of the effect of estrogen replacement therapy on the risk of breast cancer. J Am Med Assoc. 265:1991;1985-1990.
138. Hulka B.S. Links between homone replacement therapy and neoplasia. Fertil Steril. 62:1994;168-175.
139. Clinical Synthesis Panel on HRT. Clinical Synthesis Conference on Hormonal; Replacement Therapy. Lancet 1999;354:152-156.
140. Posthuma W.F., Westendorp R.G., Vandenbroucke J.P. Cardioprotective effect of hormone replacement therapy in postmenopausal women: is the evidence biased? Br Med J. 308:1994;1268-1269.
141. Gorsky R.D., Koplan J.P., Peterson H.B., Thacker S.B. Relative risks and benefits of long-term estrogen replacement therapy: a decision analysis. Obstet Gynecol. 83(2):1994;161-166.
142. Boyle P, Horton R, Radda G, Sharp D, Veronesi U, Walker AM. Open debate on HRT. Lancet 1998, in press.
143. Veronesi U, Maisonneuve P, Costa A, Sacchini V, Maltoni C, Robertson C, Rotmensz N, Boyle P. On behalf of the Italian Tamoxifen Study Group. Prevention of Breast cancer with Tamoxifen. The Italian Randomised Trial among Hysterectomised women. Lancet 1998;352:93-97.
144. Powles T., Eeles R., Ashley S., Easton D., Chang J., Dowsett M., Tidy A., Viggers J., Davey J. Interim analysis of the incidence of breast cancer in the Royal Marsden Hospital tamoxifen randomised chemoprevention trial. Lancet. 352(9122):1998;98-101.
145. Fisher B., Costantino J.P., Wickerham D.L., Redmond C.K., Kavanah M., Cronin W.M., Vogel V., Robidoux A., Dimitrov N., Atkins J., Daly M., Wieand S., Tan-Chiu E., Ford L., Wolmark N. Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst. 90(18):1998;1371-1388.
146. Gail M.H., Costantino J.P., Bryant J., Croyle R., Freedman L., Helzlsouer K., Vogel V. Weighing the risks and benefits of tamoxifen treatment for preventing breast cancer. J Natl Cancer Inst. 91(21):1999;1829-1846.
147. Working group on cervical cancer screening. Summary chapter. Hakama M, Miller A.B., Day N.E. Screening for cancer of the uterine cervix. 1986;133-142 IARC Scientific Publications No. 76, Lyon.
148. Miller AB, Chamberlain J, Day NE, Hakama M, Prorock PC. Cancer Screening. International Union Against Cancer, Geneva, 1991.
149. Fahs M.C., Mandelblatt J., Schechter C., Muller C. Cost effectiveness of cervical cancer screening in the elderly. Ann Int Med. 117:1992;520-527.
150. Hakama M, Magnus K, Petterson F, Storm H, Tulinius H. Effect of organised screening on the risk of cervix cancer in the Nordic countries. In: Miller AB, Chamberlain J, Day NE, Hakama M, Prorock PC, editors. Cancer screening international union against cancer. Geneva, 1991.
151. IARC Working Group on Evaluation of Cervical Screening Programmes. Screening for squamous cervical cancer : duration of low risk after negative results of cervical cytology and its implication for screening policies. Br. Med. J. 1986;293:659-664.
152. Koss L.G. The Papanicolaou test for cervical cancer detection: a triumph and a tragedy. J Am Med Acad. 261:1989;737-743.
153. Sasieni P.D., Cuzick J., Lynch-Farmery E. Estimating the efficacy of screening by auditing smear histories of women with and without cervical cancer. The National Co-ordinating Network for Cervical Screening Working Group. Br J Cancer. 73:1996;1001-1005.
154. Coibion M., Autier P. Is there a role for cervicopgraphy in the detection of the pre-malignant lesions of the cervix uteri? Br J Cancer. 70:1994;125-128.
155. Coppleson M., Reid B.L., Skladnev V.N., Dalrymple J.C. An electronic approach to the detection of pre-cancer and cancer of the uterine cervix: a preliminary evaluation of Polarprobe. Int J Cancer. 4:1994;79-83.
156. Cuzick J., Szarewski A., Terry G., Ho L., Hanby A., Maddox P. et al. Human papillomavirus testing in primary cervical screening. Lancet. 345:1995;1533-1536.
157. Meijer C.J., van den Brulle A.J., Snijders P.J., Helmerhorst T., Kenemans P., Walboomers J.M. Munoz N., Bosch F.X., Shah K.V., Meheus A. The epidemiology of cervical cancer and human papillomavirus. 1992;271-281 IARC Sci Public 119, Lyon.
158. Wald N.J., Chamberlain J., Hackshaw A., Anderson T., Boyle P., Forrest P. et al. Report of the European Society of Mastology EUSOMA Breast Cancer Screening Evaluation Committee. The Breast. 2:1993209216.
159. Chen H.H., Duffy S.W., Tabar L., Day N.E. Markov chain models for progression of breast cancer. Part I: tumour attributes and the pre-clinical screen-detectable phase. J Epi Bio. 2:1997;9-24.
160. Chen H.H., Duffy S.W., Tabar L., Day N.E. Markov chain models for progression of breast cancer. Part II: tumour attributes and the pre-clinical screen-detectable phase. J Epi Bio. 2:1997;25-37.
161. Breast-cancer screening with mammography in women aged 40-49 years. Int J Cancer. 68:1996;693-699.
162. News and comments. The breast-screening brawl. Science 1997;275:1056-1059.
163. Thomas D.B., Gao D.L., Self S.G., Allison C.J., Tao Y., Mahloch J. et al. Randomized trial of breast examination in Shanghai: methodology and preliminary results. J Natl Cancer Inst. 89:1997;355-365.
164. Semiglazov V.F., Sagaidak V.N., Moiseyenko V.M., Mikhailov E.A. Study of the role of breast self-examination in the reduction of mortality from breast cancer. The Russian Federation/World Health Organisation Study. Eur J Cancer. 29:1993;2039-2046.
165. Berrino F., Sant M., Verdacchia A., Capocaccia R., Hakulinen T., Esteve J. Survival of cancer patients in Europe: the EUROCARE study. International agency for research on cancer. 1995;IARC, Lyon.
166. Carnon A.G., Ssemwogerere A., Lamont D.W., Hole D.J., Mallon E.A., George W.D. et al. Relation between socioeconomic deprivation and pathological prognostic factors in women with breast cancer. Br Med J. 309:1994;1054-1057.
167. Gillis C.R., Hole D.J. Survival outcome of care by specialist surgeons in breast cancer: a study of 3786 patients in the west of Scotland. Br J Med. 312:1996;145-148.
168. Ries L.A. Ovarian cancer. Survival and treatment differences by age. Cancer. 71:1993;524-529.
169. Markman M., Lewis J.L., Saigo P., Hakes T., Rubin S., Jones W. et al. Impact of age on survival of patients with ovarian cancer. Gynecol Oncol. 49:1993;236-239.
170. Junor E.J., Hole D.J., Gillis C.R. Management of ovarian cancer: referral to a multidisciplinary team matters. Br J Cancer. 70:1994;363-370.
171. Woodman C., Baghdady A., Collins S., Clyma J.A. What changes in the organisation of cancer services will improve the outcome for women with ovarian cancer? Br J Obstet Gynaecol. 104:1997;135-139.
172. Lamont D.W., Symonds R.P., Brodie M.M., Nwabineli N.J., Gillis C.R. Age, socio-economic status and survival from cancer of cervix in the west of Scotland 1980-1987. Br J Cancer. 67:1993;351-357.
173. Boyle P., Veronesi U., Tubiana M., Alexander F.E., Calais da Silva F., Denis L.J. et al. Special paper. European School of Oncology Advisory Report to the European Commission for the Europe Against Cancer Programme. European Code Against Cancer. Eur J Cancer. 9:1995;1395-1405.
174. Parkin D.M., Stjernsward J., Muir C.S. Estimates of the world-wide frequency of twelve major cancers. Bull WHO. 62:1984;163-182.
175. Parkin D.M., Laara E., Muir C.S. Estimates of the worldwide frequency of sixteen major cancers in 1980. Int J Cancer. 41:1988;184-197.
176. Parkin D.M., Pisani P., Ferlay J. Estimates of the worldwide frequency of sixteen major cancers in 1985. Int J Cancer. 54:1993;594-606.
177. Parkin DM, Muir CS, Whelan S, et al, (eds) Cancer Incidence in Five Continents Volume VII, IARC Sci Publ 1997; 120.
178. Parkin D.M., Whelan S.L., Ferlay J., Raymond L., Young J. Cancer incidence in five continents, vol 7. 1997;International Agency for Research on Cancer IARC, Lyon.